- Report
- April 2025
- 282 Pages
Global
From €5166EUR$5,450USD£4,316GBP
- Report
- December 2024
- 75 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Report
- May 2024
- 138 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- April 2024
- 160 Pages
Global
From €4710EUR$4,969USD£3,935GBP
- Report
- March 2024
- 150 Pages
Global
From €4597EUR$4,850USD£3,840GBP
- Report
- February 2024
- 150 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1896EUR$2,000USD£1,584GBP
Cervical Dystonia Drug is a type of drug used to treat a neurological disorder characterized by involuntary muscle contractions in the neck and shoulder area. It is a form of Central Nervous System (CNS) drug, which is used to treat a variety of neurological conditions. Cervical Dystonia Drug works by blocking the release of certain neurotransmitters in the brain, which helps to reduce the muscle contractions. Common side effects of these drugs include dry mouth, blurred vision, and drowsiness.
The Cervical Dystonia Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of the disorder, as well as the development of new and improved treatments. The market is expected to continue to grow in the coming years, as more effective treatments become available.
Some of the major companies in the Cervical Dystonia Drug market include Allergan, Merz Pharmaceuticals, Teva Pharmaceuticals, and AbbVie. These companies are actively developing new treatments for the disorder, as well as providing existing treatments to patients. Show Less Read more